Monday, November 23, 2015 5:30:39 AM
http://www.theflyonthewall.com/permalinks/entry.php?symbol=chrs
Coherus Biosciences initiated with an Overweight at Barclays
Barclays analyst Douglas Tsao started Coherus Biosciences with an Overweight rating saying the company's exclusive focus on biosimilars should allow it to "navigate the patent landscape nimbly" and meet the "high bar" for U.S. approval with label extrapolation. The analyst put a $46 price target on the stock.
http://www.theflyonthewall.com/permalinks/entry.php/MNTAid1549747/MNTA-Momenta-Pharma-to-host-conference-call
Momenta initiated with an Equal Weight at Barclays
Barclays analyst Douglas Tsao started Momenta Pharmaceuticals with an Equal Weight rating saying the stock is likely to trade on Glatopa adoption, which he feels is unlikely to hit inflection in the near term. The analyst has a $22 price target for shares.
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM